NASDAQ$AGIO
Agios Pharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Agios reported business highlights and financial results, generating $3.1 million in U.S. net revenue for PYRUKYND sales.
Agios Pharmaceuticals reported Q2 2022 financial results, including $3.1 million in U.S. net revenue from PYRUKYND sales and $2.5 million from licensing intellectual property. The company had $1.1 billion in cash, cash equivalents, and marketable securities as of June 30, 2022.
- Generated $3.1 million in U.S. net revenue from PYRUKYND® sales, the first full quarter following FDA approval.
- Initiated Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies of PYRUKYND® in pediatric patients with PK deficiency.
- Brian Goff to become Chief Executive Officer at Agios on August 8, 2022.
- Evolved Agios’ research approach to focus on advancing existing preclinical programs and in-licensing or acquiring well-characterized, high-potential assets.
Headline financials
Revenue & EPS history
Agios · Revenue · Quarterly
$5.58M
Forward guidance
Agios expects to execute on key milestones and priorities in 2022.
Tailwinds
- Receive European Medicines Agency (EMA) regulatory decision for PYRUKYND® in adults with PK deficiency by year-end.
- Enroll a meaningful portion of patients in the Phase 3 ENERGIZE and ENERGIZE-T studies of PYRUKYND® in not regularly transfused and regularly transfused adults with thalassemia, respectively, by year-end.
- Complete enrollment in the Phase 2 portion of the RISE UP study of PYRUKYND® in sickle cell disease by year-end.
- Initiate Phase 2a study of AG-946 in adults with low- to intermediate-risk MDS by year-end.
- Continue to publish clinical and translational data supporting the utility of PK activators across key disease areas and elucidating the burden of disease for PK deficiency, thalassemia and sickle cell disease.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.0%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.9%
Avg return
30 days after
50%
25 / 50 earnings
Positive
+19.2%
Q2 2022
Best reaction
-15.0%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +11.1% | +18.5% | |
| Q4 2025 | +1.3% | +0.4% | +0.5% | |
| Q3 2025 | +2.8% | -4.7% | -30.4% | |
| Q1 2025 | +4.2% | -4.6% | +8.1% | |
| Q4 2024 | +1.5% | +2.4% | -5.7% | |
| Q3 2024 | -3.1% | +0.9% | +28.3% | |
| Q2 2024 | -5.3% | -8.2% | -1.1% | |
| Q1 2024 | +2.6% | -2.6% | +8.0% | |
| Q4 2023 | +2.4% | +4.6% | +15.6% | |
| Q3 2023 | +5.6% | +9.1% | +7.5% | |
| Q2 2023 | -2.0% | +0.1% | +8.4% | |
| Q1 2023 | +11.7% | +11.1% | +13.9% | |
| Q4 2022 | -5.3% | -4.6% | -18.0% | |
| Q3 2022 | -6.9% | -2.0% | +13.3% | |
| Q2 2022 | +19.2% | +9.7% | +27.7% | |
| Q1 2022 | -6.3% | -9.7% | -18.5% | |
| Q4 2021 | +11.8% | +16.9% | +4.5% | |
| Q3 2021 | -7.3% | -9.1% | -31.3% | |
| Q2 2021 | -3.8% | -5.8% | -9.9% | |
| Q1 2021 | +0.7% | -3.4% | +0.6% | |
| Q4 2020 | -10.3% | -7.5% | -6.1% | |
| Q3 2020 | -5.5% | +0.2% | +7.7% | |
| Q2 2020 | -8.3% | -10.7% | -18.9% | |
| Q1 2020 | -15.0% | -9.4% | +18.8% | |
| Q4 2019 | +4.3% | +7.9% | -24.9% | |
| Q3 2019 | +6.4% | +9.2% | +23.0% | |
| Q2 2019 | -12.6% | -15.5% | -21.1% | |
| Q1 2019 | +3.2% | -5.1% | -13.2% | |
| Q4 2018 | +9.7% | +6.8% | +20.3% | |
| Q3 2018 | +11.6% | +13.1% | +4.3% | |
| Q2 2018 | -9.0% | -7.3% | -6.9% | |
| Q1 2018 | -0.9% | +1.1% | +17.5% | |
| Q4 2017 | +3.0% | +1.5% | +8.4% | |
| Q3 2017 | +0.0% | +3.6% | -4.8% | |
| Q2 2017 | -0.8% | -3.6% | +4.5% | |
| Q1 2017 | +6.8% | +7.5% | +5.1% | |
| Q4 2016 | +17.3% | +9.3% | +16.3% | |
| Q3 2016 | +7.3% | +17.2% | +23.6% | |
| Q2 2016 | -6.3% | -11.0% | -21.0% | |
| Q1 2016 | -7.2% | — | — | |
| Q4 2015 | -8.3% | — | — | |
| Q3 2015 | -2.6% | — | — | |
| Q2 2015 | -12.4% | — | — | |
| Q1 2015 | +13.3% | — | — | |
| Q4 2014 | -7.3% | — | — | |
| Q3 2014 | -1.6% | — | — | |
| Q2 2014 | +1.4% | — | — | |
| Q1 2014 | -10.3% | — | — | |
| Q3 2013 | +3.2% | — | — | |
| Q2 2013 | +6.4% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro